Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Strategic Alliance Partners

September 08, 2022

Indiana University School of Medicine has named Shelley Johns, PsyD, ABPP, the Walther Scholar in Psycho-Oncology.

July 15, 2022

Analyzing nearly 500,000 single cells, researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are refining how to classify colorectal cancer and identify new targets to develop effective therapies.

May 27, 2022

A gift commitment of $12.5 million to Indiana University School of Medicine from the Vera Bradley Foundation for Breast Cancer will support new research to harness immunotherapy for breast cancer treatment.

May 23, 2022

Kelvin P. Lee, MD, discusses the importance of collaboration in precision medicine.

April 27, 2022

Kelvin P. Lee, MD, discusses the importance of sequencing in precision medicine.

April 27, 2022

A researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center found the COVID-19 vaccine protected most cancer patients from getting COVID. However, patients with certain types of cancer have a higher and widely varied risk of breakthrough COVID infections after receiving the COVID vaccine.

February 24, 2022

December 24, 2020

Michael J. Robertson, MD, discusses the value of fellowship, choosing a career path, and the second epiphany that led him to focus on one of the hottest topics in oncology years before it became a viable treatment option.

October 07, 2020

Indiana University School of Medicine has announced the hiring of a world-recognized medical oncologist and multiple myeloma researcher to lead the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

October 08, 2019

Roberto Pili, MD, discusses clinical challenges in translocation renal cell carcinoma.

May 22, 2018

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the importance of differentiating between neuroendocrine tumors (NETs).

April 20, 2018

Paul R. Helft, MD, discusses the incidence of gastrointestinal neuroendocrine tumors and available and emerging treatment methods.

April 03, 2018

Paul R. Helft, MD, professor of medicine, Indiana University School of Medicine, Indiana University Health Melvin and Bren Simon Cancer Center, discusses pancreatic and carcinoid neuroendocrine tumors.

October 14, 2016

With the growing body of evidence supporting positive outcomes with the use of precision medicine–based approaches, academic cancer centers are increasingly incorporating genomic technology into standard clinical care.

June 14, 2016

The program brings both high-school and undergraduate students from underrepresented populations to the IU School of Medicine's Indianapolis campus. It offers students positive and meaningful firsthand exposure to biomedical and behavioral science careers that might not otherwise present themselves.

March 25, 2016

To address the unmet need for better diagnostic and therapeutic modalities in pancreatic cancer, investigators at the Indiana University School of Medicine have established the Pancreatic Cancer Signature Center at the Indiana University Melvin and Bren Simon Cancer Center.

June 15, 2015

Olanzapine (Zyprexa) demonstrated an improvement in antinausea effects in patients receiving concurrent highly emetogenic chemotherapy and radiation therapy for advanced stage head and neck and esophageal cancer when compared to fosaprepitant.

May 24, 2015

Thousands of women have made the selfless choice to literally donate a precious piece of themselves by giving a breast tissue sample to the Susan G. Komen Tissue Bank at the Indiana University Melvin and Bren Simon Cancer Center, a unique resource for researchers worldwide.

March 03, 2015

OncLive and Indiana University Melvin and Bren Simon Cancer Center have joined forces to share news about the center's research and education programs, OncLive announced today. The collaboration is part of OncLive's Strategic Alliance Partnership initiative.

July 01, 2014

Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses new methods being explored to help improve the cure rate in prostate cancer.